+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 221 Pages
  • January 2021
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5241451
The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period. Antibiotic is a substance that fights against bacterial and protozoan infections. Additionally, they help in treating many diseases like urinary tract infections, pneumonia, strep throat, skin infections, sinus infections, ear infections and many more. Antibiotics can be classified on various bases but the most common classification is done on the basis of spectrum of activity, chemical structures, and mode of action. Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.

The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases. Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market. On the other hand, advanced prospect molecules and the development of novel combination therapies to cure antibiotic-resistant microbial infections are estimated to propel the market and provide great opportunities for the market players.

The increased cases of infectious diseases in developing regions like the Asia Pacific and the Middle East are estimated to support the market growth. According to the data provided by WHO, above 15% of the children’s death is caused by pneumonia. Similarly, tuberculosis is more prevalent in the South Asian and Sub-Saharan regions. Presently, the much-needed antibiotic treatment is accessible only to one-third of the infected population that further expands the disease burden.



By Action Mechanism

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. RNA and Folic acid synthesis inhibitors are expected to witness notable CAGRs during the forecast period. The evolutions of various antiviral drugs that inhibit transcription and reverse transcription processes are expected to help in the growth of the market. Folic acid inhibitor sulfa drugs are estimated to expand as they have a broad range of applications.



By Drug Class

Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. The other antibiotics category includes imidazoles, tetracyclines, monoclonal antibodies, and lincosamides. It is expected that the other antibiotic category will expand at a high CAGR over the forecast period. The innovation of monoclonal antibodies for people who have developed antibiotic-resistance is the main feature of this category.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America continues to attain a high market share in the antibiotic market worldwide. The Healthcare System in North America helps in the utilization of branded products, although, with the loss of exclusivity of certain molecules, sales of the region have declined significantly in the last few years. Latin America, specifically Brazil, with its notable growth in the pharmaceuticals industry is also expected to boost the growth of the market. The outbreak of some viruses like Ebola in Africa is anticipated to push the growth of the market in this region.


The major strategies followed by the market participants are Acquisition and Partnerships. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis AG are some of the forerunners in the Antibiotics Market. Companies such as Sanofi S.A., Bayer AG, etc. are some of the key innovators in Antibiotics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Strategies deployed in Antibiotics Market

Nov-2020: Merck & Co. introduced its novel antibiotic combination Recarbrio in the UK. The antibiotic cure infections caused by aerobic Gram-negative organisms in adults with finite treatment options.

Oct-2020: Pfizer agreed to acquire Arixa, a private real estate lender. The acquisition will help Pfizer to advance the development program for Arixa’s leading asset, ARX-1796. The potential benefits of ARX-1796 provide patients and the healthcare system and potentially enable patients to leave the hospital earlier or avoid the requirement for the hospital admission.

Aug-2020: Sanofi signed an agreement to acquire Principia Biopharma, a late-stage biopharmaceutical company. The acquisition will help Sanofi to expand its autoimmune disease drug line. It also helps in advancing their R&D transformation to boost the development of the most promising medicines that will address significant patient requirements.

Jul-2020: Novartis together with its biosimilars division Sandoz signed an agreement with the Austrian Federal Government. The agreement aimed to strengthen the long-term future of integrated antibiotics manufacturing in Europe.

Jun-2020: Roche came into partnership with SpeeDx Pty. Ltd., an Australian-based private company. The partnership is a significant inflection point for the company and enables more patients and clinicians around the world. It also allows access to the key diagnostic tools for the management of antibiotic resistance.

Apr-2020: Sanofi entered into a collaboration with GSK, a British multinational pharmaceutical company. The collaboration aimed to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies. This technology produced an exact genetic match to proteins found on the surface of the virus. The DNA sequence encodes this antigen, combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.

Mar-2020: La Roche entered into a collaboration with Forge Therapeutics, a biotechnology company. The collaboration aimed to license FG-LpxC LUNG, a novel antibiotic for curing serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. The FG-LpxC LUNG program is developed to cure hospital-based infections, which include those cited on the CDC's most urgent threats list that commonly occurs in people with weakened immune systems and chronic lung diseases.

Jan-2020: Sanofi took over Synthorx, a biotechnology company. This acquisition added on to its synthorin drugs for cancer and autoimmune indications to its pipeline. Synthorins are proteins that are altered by using a base pair technique to enhance their characteristics.

Dec-2019: Johnson & Johnson is acquiring Bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in Phase 2 development for curing atopic dermatitis and hidradenitis suppurativa. The acquisition will help the company to improve its ability to assist patients, providing their decades-long heritage and intense expertise in immunology.

Jul-2019: Merck & Co. announced the approval of Recarbrio by the FDA. Recarbrio is an injection antibiotic for adult patients with complicated urinary tract infections, or cUTIs, with limited or no treatment options. Along with that, it also cures adults with certain complicated intra-abdominal infections, or cIAIs, and which have limited or no treatment options.

Oct-2018: Novartis entered into an agreement with Boston Pharmaceuticals, a biopharmaceutical company. The agreement aimed to develop three novel anti-infective drug candidates, adding to the Novartis Infectious Diseases portfolio. The portfolio has the potential to address the requirement for new agents to cure antibiotic resistant Gram-negative infections.

Oct-2017: Roche partnered with Warp Drive Bio, a subsidiary of Revolution Medicines. The partnership focused on the development of new classes of antibiotics against multidrug-resistant bacterial infections. Together, they designed to advance multiple novel classes of natural antibiotics that show activity against clinically important, drug-resistant, Gram-negative pathogens by applying Warp Drive’s Genome Mining platform.

Mar-2017: Pfizer introduced Zavicefta, a novel combination antibiotic. Zavicefta treats patients with certain confirmed or suspected Gram-negative bacterial infections who needed hospitalization, available in the U.K. and Germany. Zavicefta was developed in response to the urgent medical requirement for new antibiotics for difficult-to-treat Gram-negative bacteria.

Jan-2017: Johnson & Johnson agreed to acquire Actelion Ltd, a pharmaceuticals and biotechnology company. The acquisition helped Actelion’s specialty in-market medicines and late-stage products compatible with Johnson & Johnson’s efforts to expand the attractive and complementary therapeutic areas and deliver patients with serious illnesses and significant unmet medical requirements.

Aug-2016: Pfizer acquired AstraZeneca's development and commercialization rights to its late-stage small molecule anti-infectives business. The introduction of AstraZeneca’s complementary small molecule anti-infectives portfolio helped in expanding patient access to these important medicines. It also enhanced their global expertise and offerings in the important area of therapeutics. Additionally, they provide the opportunity for near-term revenue to grow.

Scope of the Study

Market Segments covered in the Report:

By Action Mechanism
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors,
  • Mycolic Acid Inhibitors

By Drug Class
  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides,
  • Others

By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled
  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Antibiotics Market, by Action Mechanism
1.4.2 Global Antibiotics Market, by Drug Class
1.4.3 Global Antibiotics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals
3.2.4 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players
Chapter 4. Global Antibiotics Market by Action Mechanism
4.1 Global Cell Wall Synthesis Inhibitors Market by Region
4.2 Global Protein Synthesis Inhibitors Market by Region
4.3 Global DNA Synthesis Inhibitors Market by Region
4.4 Global RNA Synthesis Inhibitors Market by Region
4.5 Global Mycolic Acid Inhibitors Market by Region
Chapter 5. Global Antibiotics Market by Drug Class
5.1 Global Cephalosporin Market by Region
5.2 Global Penicillin Market by Region
5.3 Global Fluoroquinolone Market by Region
5.4 Global Macrolides Market by Region
5.5 Global Carbapenem Market by Region
5.6 Global Aminoglycosides Market by Region
5.7 Global Sulfonamides Market by Region
5.8 Global Others Market by Region
Chapter 6. Global Antibiotics Market by Region
6.1 North America Antibiotics Market
6.1.1 North America Antibiotics Market by Action Mechanism
6.1.1.1 North America Cell Wall Synthesis Inhibitors Market by Country
6.1.1.2 North America Protein Synthesis Inhibitors Market by Country
6.1.1.3 North America DNA Synthesis Inhibitors Market by Country
6.1.1.4 North America RNA Synthesis Inhibitors Market by Country
6.1.1.5 North America Mycolic Acid Inhibitors Market by Country
6.1.2 North America Antibiotics Market by Drug Class
6.1.2.1 North America Cephalosporin Market by Country
6.1.2.2 North America Penicillin Market by Country
6.1.2.3 North America Fluoroquinolone Market by Country
6.1.2.4 North America Macrolides Market by Country
6.1.2.5 North America Carbapenem Market by Country
6.1.2.6 North America Aminoglycosides Market by Country
6.1.2.7 North America Sulfonamides Market by Country
6.1.2.8 North America Others Market by Country
6.1.3 North America Antibiotics Market by Country
6.1.3.1 US Antibiotics Market
6.1.3.1.1 US Antibiotics Market by Action Mechanism
6.1.3.1.2 US Antibiotics Market by Drug Class
6.1.3.2 Canada Antibiotics Market
6.1.3.2.1 Canada Antibiotics Market by Action Mechanism
6.1.3.2.2 Canada Antibiotics Market by Drug Class
6.1.3.3 Mexico Antibiotics Market
6.1.3.3.1 Mexico Antibiotics Market by Action Mechanism
6.1.3.3.2 Mexico Antibiotics Market by Drug Class
6.1.3.4 Rest of North America Antibiotics Market
6.1.3.4.1 Rest of North America Antibiotics Market by Action Mechanism
6.1.3.4.2 Rest of North America Antibiotics Market by Drug Class
6.2 Europe Antibiotics Market
6.2.1 Europe Antibiotics Market by Action Mechanism
6.2.1.1 Europe Cell Wall Synthesis Inhibitors Market by Country
6.2.1.2 Europe Protein Synthesis Inhibitors Market by Country
6.2.1.3 Europe DNA Synthesis Inhibitors Market by Country
6.2.1.4 Europe RNA Synthesis Inhibitors Market by Country
6.2.1.5 Europe Others Market by Country
6.2.2 Europe Antibiotics Market by Drug Class
6.2.2.1 Europe Cephalosporin Market by Country
6.2.2.2 Europe Penicillin Market by Country
6.2.2.3 Europe Fluoroquinolone Market by Country
6.2.2.4 Europe Macrolides Market by Country
6.2.2.5 Europe Carbapenem Market by Country
6.2.2.6 Europe Aminoglycosides Market by Country
6.2.2.7 Europe Sulfonamides Market by Country
6.2.2.8 Europe Others Market by Country
6.2.3 Europe Antibiotics Market by Country
6.2.3.1 Germany Antibiotics Market
6.2.3.1.1 Germany Antibiotics Market by Action Mechanism
6.2.3.1.2 Germany Antibiotics Market by Drug Class
6.2.3.2 UK Antibiotics Market
6.2.3.2.1 UK Antibiotics Market by Action Mechanism
6.2.3.2.2 UK Antibiotics Market by Drug Class
6.2.3.3 France Antibiotics Market
6.2.3.3.1 France Antibiotics Market by Action Mechanism
6.2.3.3.2 France Antibiotics Market by Drug Class
6.2.3.4 Russia Antibiotics Market
6.2.3.4.1 Russia Antibiotics Market by Action Mechanism
6.2.3.4.2 Russia Antibiotics Market by Drug Class
6.2.3.5 Spain Antibiotics Market
6.2.3.5.1 Spain Antibiotics Market by Action Mechanism
6.2.3.5.2 Spain Antibiotics Market by Drug Class
6.2.3.6 Italy Antibiotics Market
6.2.3.6.1 Italy Antibiotics Market by Action Mechanism
6.2.3.6.2 Italy Antibiotics Market by Drug Class
6.2.3.7 Rest of Europe Antibiotics Market
6.2.3.7.1 Rest of Europe Antibiotics Market by Action Mechanism
6.2.3.7.2 Rest of Europe Antibiotics Market by Drug Class
6.3 Asia Pacific Antibiotics Market
6.3.1 Asia Pacific Antibiotics Market by Action Mechanism
6.3.1.1 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country
6.3.1.2 Asia Pacific Protein Synthesis Inhibitors Market by Country
6.3.1.3 Asia Pacific DNA Synthesis Inhibitors Market by Country
6.3.1.4 Asia Pacific RNA Synthesis Inhibitors Market by Country
6.3.1.5 Asia Pacific Mycolic Acid Inhibitors Market by Country
6.3.2 Asia Pacific Antibiotics Market by Drug Class
6.3.2.1 Asia Pacific Cephalosporin Market by Country
6.3.2.2 Asia Pacific Penicillin Market by Country
6.3.2.3 Asia Pacific Fluoroquinolone Market by Country
6.3.2.4 Asia Pacific Macrolides Market by Country
6.3.2.5 Asia Pacific Carbapenem Market by Country
6.3.2.6 Asia Pacific Aminoglycosides Market by Country
6.3.2.7 Asia Pacific Sulfonamides Market by Country
6.3.2.8 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Antibiotics Market by Country
6.3.3.1 China Antibiotics Market
6.3.3.1.1 China Antibiotics Market by Action Mechanism
6.3.3.1.2 China Antibiotics Market by Drug Class
6.3.3.2 Japan Antibiotics Market
6.3.3.2.1 Japan Antibiotics Market by Action Mechanism
6.3.3.2.2 Japan Antibiotics Market by Drug Class
6.3.3.3 India Antibiotics Market
6.3.3.3.1 India Antibiotics Market by Action Mechanism
6.3.3.3.2 India Antibiotics Market by Drug Class
6.3.3.4 South Korea Antibiotics Market
6.3.3.4.1 South Korea Antibiotics Market by Action Mechanism
6.3.3.4.2 South Korea Antibiotics Market by Drug Class
6.3.3.5 Singapore Antibiotics Market
6.3.3.5.1 Singapore Antibiotics Market by Action Mechanism
6.3.3.5.2 Singapore Antibiotics Market by Drug Class
6.3.3.6 Malaysia Antibiotics Market
6.3.3.6.1 Malaysia Antibiotics Market by Action Mechanism
6.3.3.6.2 Malaysia Antibiotics Market by Drug Class
6.3.3.7 Rest of Asia Pacific Antibiotics Market
6.3.3.7.1 Rest of Asia Pacific Antibiotics Market by Action Mechanism
6.3.3.7.2 Rest of Asia Pacific Antibiotics Market by Drug Class
6.4 LAMEA Antibiotics Market
6.4.1 LAMEA Antibiotics Market by Action Mechanism
6.4.1.1 LAMEA Cell Wall Synthesis Inhibitors Market by Country
6.4.1.2 LAMEA Protein Synthesis Inhibitors Market by Country
6.4.1.3 LAMEA DNA Synthesis Inhibitors Market by Country
6.4.1.4 LAMEA RNA Synthesis Inhibitors Market by Country
6.4.1.5 LAMEA Others Market by Country
6.4.2 LAMEA Antibiotics Market by Drug Class
6.4.2.1 LAMEA Cephalosporin Market by Country
6.4.2.2 LAMEA Penicillin Market by Country
6.4.2.3 LAMEA Fluoroquinolone Market by Country
6.4.2.4 LAMEA Macrolides Market by Country
6.4.2.5 LAMEA Carbapenem Market by Country
6.4.2.6 LAMEA Aminoglycosides Market by Country
6.4.2.7 LAMEA Sulfonamides Market by Country
6.4.2.8 LAMEA Others Market by Country
6.4.3 LAMEA Antibiotics Market by Country
6.4.3.1 Brazil Antibiotics Market
6.4.3.1.1 Brazil Antibiotics Market by Action Mechanism
6.4.3.1.2 Brazil Antibiotics Market by Drug Class
6.4.3.2 Argentina Antibiotics Market
6.4.3.2.1 Argentina Antibiotics Market by Action Mechanism
6.4.3.2.2 Argentina Antibiotics Market by Drug Class
6.4.3.3 UAE Antibiotics Market
6.4.3.3.1 UAE Antibiotics Market by Action Mechanism
6.4.3.3.2 UAE Antibiotics Market by Drug Class
6.4.3.4 Saudi Arabia Antibiotics Market
6.4.3.4.1 Saudi Arabia Antibiotics Market by Action Mechanism
6.4.3.4.2 Saudi Arabia Antibiotics Market by Drug Class
6.4.3.5 South Africa Antibiotics Market
6.4.3.5.1 South Africa Antibiotics Market by Action Mechanism
6.4.3.5.2 South Africa Antibiotics Market by Drug Class
6.4.3.6 Nigeria Antibiotics Market
6.4.3.6.1 Nigeria Antibiotics Market by Action Mechanism
6.4.3.6.2 Nigeria Antibiotics Market by Drug Class
6.4.3.7 Rest of LAMEA Antibiotics Market
6.4.3.7.1 Rest of LAMEA Antibiotics Market by Action Mechanism
6.4.3.7.2 Rest of LAMEA Antibiotics Market by Drug Class
Chapter 7. Company Profiles
7.1 GlaxoSmithKline PLC (GSK)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Johnson and Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Product Launches and Product Expansions:
7.3.1.2 Approvals:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Acquisition and Mergers:
7.4.4.2 Product Launches and Product Expansions:
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Acquisition and Mergers:
7.7.5.2 Partnerships, Collaborations, and Agreements:
7.8 Abbott Laboratories
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

Companies Mentioned

  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company

Methodology

Loading
LOADING...